RTSN· Health Care› Biotechnology

Retension Pharmaceuticals, Inc.

$15.50

-2.52% today

$129M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

—

Edge

—

Is RTSN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-10-09 → 2026-10-22

S? 2w

2026-10-092026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 2w current

Total tracked: 2 weeks across 1 stage run.

RTSN among Biotechnology576th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…576	RTSNRetension Pharmaceuticals, Inc.	—	—	—

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 2

1w13w26w

Week 2, fresh breakout

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

—

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

—

Not enough history yet

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

—

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 2 · Vol —x

2026-10-21S—

Wk 2 · Vol —x

2026-10-20S—

Wk 2 · Vol —x

2026-10-19S—

Wk 2 · Vol —x

2026-10-16S—

Wk 2 · Vol —x

2026-10-15S—

Wk 1 · Vol —x

2026-10-14S—

Wk 1 · Vol —x

2026-10-13S—

Wk 1 · Vol —x

2026-10-12S—

Wk 1 · Vol —x

2026-10-09S—

Wk 1 · Vol —x

Moving averages & range

50 DMA

—

200 DMA

—

52W High

—

52W Low

—

5D Low

$14.07

Resistance levels (recent highs)

20d High

—

60d High

—

120d High

—

250d High

—

Next resistance

Above all

Dividend Yield

0.00%

P/B -0.8

Retension Pharmaceuticals: quick answers

Which sector and industry is Retension Pharmaceuticals in?

Retension Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.